Why Novartis (NVS) is a Top Value Stock for the Long-Term

Novartis (NVS) is highlighted as a compelling value investment, maintaining a dominant pharmaceutical position through a robust drug portfolio, strategic M&A, and focus on core therapeutic areas. The company holds a Zacks Rank #2 (Buy) with a VGM Score of B and a Value Style Score of B, supported by an attractive forward P/E of 13.61. Recent upward revisions to its FY2025 earnings estimate, now at $9.00 per share, and a consistent +6.2% average earnings surprise further underscore its positive investment outlook.

Analysis

Novartis (NVS) is positioned as a strong value investment based on a combination of strategic portfolio optimization and positive forward-looking financial metrics. The company has actively reshaped its business by divesting non-core assets, such as its Animal Health division and its stake in Roche, while making targeted acquisitions like The Medicines Company to secure high-potential therapies like Leqvio. This strategy has focused the company on core therapeutic areas including oncology and cardiovascular, with specific drugs like Kesimpta, Pluvicto, and Scemblix identified as key growth drivers. This fundamental strength is corroborated by quantitative signals; the stock trades at an attractive forward P/E ratio of 13.61. Furthermore, analyst sentiment is turning more positive, with two upward earnings estimate revisions for fiscal year 2025 in the last 60 days, pushing the consensus estimate to $9.00 per share. The company's consistent operational execution is evidenced by a historical average earnings surprise of +6.2%, reinforcing the investment case presented by its Zacks #2 (Buy) rank and 'B' grades for both Value and overall VGM scores.

Key Decisions for Investors

• Value-oriented investors should consider Novartis given its forward P/E of 13.61, which appears attractive relative to its defined growth drivers and a track record of beating earnings estimates by an average of 6.2%.
• Investors should monitor the revenue trajectory of newly emphasized growth products such as Kesimpta, Pluvicto, and Leqvio, as their commercial success is central to achieving the upwardly revised earnings forecasts.
• Given the company's history of strategic M&A and divestitures, it is prudent to evaluate how management continues to allocate capital to ensure it remains focused on strengthening its core, high-growth therapeutic areas.
• The positive analyst estimate revisions for FY2025 suggest growing confidence, so investors should watch for continued consensus upgrades as a potential catalyst for the stock.